This HTML5 document contains 143 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1080/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q48305155
rdf:type
wikibase:Item
schema:description
artikulong pang-agham 2018年学术文章 article scientifique (publié 2018) vědecký článek artículo científico publicado en 2018 2018 nî lūn-bûn tudományos cikk 2018年学术文章 مقالة علمية 2018年學術文章 ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articol științific научная статья vitenskapelig artikkel מאמר מדעי artykuł naukowy 2018年学术文章 artikull shkencor 2018年學術文章 2018年学术文章 наукова стаття, опублікована в січні 2018 tieteellinen artikkeli wetenschappelijk artikel bilimsel makale სამეცნიერო სტატია научни чланак artigo científico (publicado na 2018) artigo científico article scientific مقالهٔ علمی scienca artikolo سائنسی مضمون mokslinis straipsnis vitskapeleg artikkel vedecký článok teaduslik artikkel научни чланак videnskabelig artikel (udgivet 2018) 2018년 논문 2018年學術文章 บทความทางวิทยาศาสตร์ articolo scientifico научна статия 2018年學術文章 artigo científico (publicado na 2018) գիտական հոդված 2018年の論文 επιστημονικό άρθρο 2018年学术文章 article científic scientific article мақолаи илмӣ wissenschaftlicher Artikel 2018年學術文章 artículu científicu мақолаи илмӣ 2018年學術文章 vetenskaplig artikel bài báo khoa học naučni članak
p:P577
wds:Q48305155-F1B8F4B0-E8FB-480A-A6BA-9393B509D193
wdt:P577
2018-01-05T00:00:00Z
p:P2860
wds:Q48305155-0AF1F1AE-11E5-4599-8A37-B10B314704EF wds:Q48305155-127E2490-A242-41EE-BADD-F313F694D539 wds:Q48305155-15B1065E-D1B5-4273-BC4C-E2B4B98C124A wds:Q48305155-176A388A-8F31-4ABB-B60A-16CD25B2ECAE wds:Q48305155-27CEBF35-58C7-40AB-B19D-99F804C0B1ED wds:Q48305155-30727115-55FC-40C1-8AD9-CB5E09A25A88 wds:Q48305155-EC853010-3AE6-4B80-B7C9-CCEB9BB2819F wds:Q48305155-FD420259-6996-4207-A1D6-E76D6A83E179 wds:Q48305155-FEE9F059-7FC5-4849-ACA1-28EC7F53F4E7 wds:Q48305155-C9EC0049-5754-42DB-B8DE-BCCEF82E6774 wds:Q48305155-E728D45E-42F1-4083-A3A0-BAA454FB3664 wds:Q48305155-EA10149B-B31B-4CB9-AA65-A6C1B2E0F13A wds:Q48305155-A25DBCD9-6836-4A57-BE9D-F8FC199FF5D2 wds:Q48305155-A8283619-188C-4532-8712-FC24EB1AF90D wds:Q48305155-AA5A1BD6-63E4-4812-AB7B-F10811311116 wds:Q48305155-37D09D4C-6A47-4521-B0B0-1410EB32523B wds:Q48305155-4714BD7F-1256-4F23-9A97-3756AFFBC2BF wds:Q48305155-5A11975A-5CFC-4CAB-82BE-778815536325 wds:Q48305155-83D1E6F7-3098-4B51-A77B-8A8690E44E58
wdt:P2860
wd:Q38108121 wd:Q37255872 wd:Q42727447 wd:Q46080796 wd:Q24643447 wd:Q42218471 wd:Q37875966 wd:Q46120578 wd:Q52973447 wd:Q38337829 wd:Q43945171 wd:Q33806007 wd:Q38250027 wd:Q37910910 wd:Q42914703 wd:Q36192439 wd:Q40412392 wd:Q38926895 wd:Q40920244
p:P2093
wds:Q48305155-A05D2E91-E006-4BB1-A10A-791ADA959E44 wds:Q48305155-83A6BB46-7129-4E1A-9D23-972BE374CC21 wds:Q48305155-10BFC1FB-55B0-49CB-8D13-B48DA7F0AF41
wdt:P2093
Steven Ellsworth Steven I Park Xianming Tan
rdfs:label
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
skos:prefLabel
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
schema:name
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
p:P50
wds:Q48305155-733D5057-B653-4979-AF4D-2562F6C04D68 wds:Q48305155-ACBA4347-B42E-4470-B644-C53887CC7B46
wdt:P50
wd:Q88252944 wd:Q56548170
p:P1476
wds:Q48305155-BD6DB574-EB0D-4DA0-8166-9F03C2E3C3CA
wdt:P1476
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
p:P304
wds:Q48305155-3EB0341B-4D45-40B0-9162-F61AF19723C5
wdt:P304
2121-2127
p:P31
wds:Q48305155-BB9EF5E7-E997-4168-AB18-6BEE75CD302C
wdt:P31
wd:Q13442814
p:P921
wds:Q48305155-AE6D9EC4-E9C9-4240-8A7A-7E44A7ED7BCB wds:Q48305155-DEE67170-E707-4A22-9CB1-5E84950FC8B2 wds:Q48305155-E27A3F68-72A1-4823-B827-A7EDC593AF2A wds:Q48305155-B6B7669A-E7D9-497D-9B67-FA758F5B0373
wdt:P921
wd:Q2703 wd:Q418817 wd:Q17635591 wd:Q18936
p:P698
wds:Q48305155-10023CE5-5276-4681-9A57-F10DEF98B964
wdtn:P698
n11:29303024
wdt:P698
29303024
p:P1433
wds:Q48305155-8FEFCFE9-60FE-4AA6-9D28-8E845EE322D8
wdt:P1433
wd:Q6534493
p:P433
wds:Q48305155-08B0FE0B-56F1-4A79-AC44-8BA287E6E847
p:P478
wds:Q48305155-A2C9C5BA-EF86-4711-B6A9-2D5D73D343A1
wdt:P433
9
wdt:P478
59
p:P356
wds:Q48305155-46DB3809-A902-436A-AC07-B69DCB828DAC
wdtn:P356
n12:10428194.2017.1416365
wdt:P356
10.1080/10428194.2017.1416365